Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. The company reported quarterly sales of $22.519 million which missed